11 results about "Serum cholesterol" patented technology

The present invention discloses an interfering RNA for inhibiting PCSK9 gene and use thereof. The interfering RNA comprises a nucleotide sequence set forth in any one or two or more of SEQ ID NOs: 1-40, 73-96. The interfering RNA of the present invention can better target and silence hepatic PCSK9 mRNA, reduce the protein level of PCSK9, enhance LDL-C metabolism, and reduce serum cholesterol, providing a solid technical foundation for the development of siRNA medicaments for the prevention, treatment, and symptom alleviation of PCSK9 gene-mediated diseases.

The invention discloses an interfering RNA (Ribonucleic Acid) for inhibiting a PCSK9 gene and application of the interfering RNA. The interfering RNA comprises any one or more than two nucleotide sequences as shown in SEQ ID NO: 1-40 and SEQ ID NO: 73-96. The interfering RNA can better target and silence mRNA of the liver PCSK9, reduce the protein level of the PCSK9, enhance LDL-C metabolism and reduce serum cholesterol, and a solid technical basis is provided for research and development of siRNA drugs for prevention and treatment of PCSK9 gene mediated diseases and symptom relief.

The invention discloses a pediococcus pentosaceus MDL511, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 has the advantages that the preservation number is CGMCC No.35201, the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 disclosed by the invention can be used for remarkably reducing weight gain and fat growth of mice caused by high fat diet, reducing serum cholesterol, LDL-C (Low Density Lipoprotein Cholesterol) and ALT (Atomic Lymphocyte Transferase) levels and remarkably improving hepatic lesions and fat accumulation caused by high fat diet, so that the MDL511 has a blood fat reducing effect, can be used for preparing blood fat reducing products and weight losing products and has a good development prospect.

The present invention provides a method for determining a mortality risk and / or probability of healthy lifespan of a cat; said method comprising determining the level of one or more biomarker(s) in one or more samples obtained from the cat, wherein the one or more biomarker(s) is selected from white blood cell count, haemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, and / or serum GGT.

This invention belongs to the field of traditional Chinese medicine technology. More specifically, it relates to the application of a processed product of Citrus reticulata peel or Citrus reticulata peel embryo (with bitterness removed) in the preparation of products for lowering lipids and preventing and treating hyperlipidemia. Compared with the original product, the processed product of Citrus reticulata peel or Citrus reticulata peel embryo provided by this invention significantly reduces bitterness while significantly enhancing its effects in lowering cholesterol and triglycerides and regulating blood lipids. This processed product helps maintain normal levels of serum cholesterol, triglycerides, and low-density lipoprotein, and can significantly improve liver damage caused by hyperlipidemia, thus having important application value in lowering lipids and protecting the liver.

The invention provides curcumin composite nanoparticles capable of reducing serum cholesterol and a preparation method of the curcumin composite nanoparticles, and belongs to the technical field of nutritional active ingredient delivery systems. The curcumin-zein-chondroitin sulfate composite nanoparticles are prepared by mixing curcumin, zein and chondroitin sulfate stock solution in equal volume for reaction and then using an anti-solvent coprecipitation method. Compared with free curcumin, the curcumin-zein-chondroitin sulfate composite nanoparticles have better physical and chemical stability, biological activity and efficacy, and have a stronger blood fat reducing effect. According to the method provided by the invention, the physical and chemical stability and the efficacy performance of the curcumin are remarkably improved, and the curcumin has a good application prospect in the aspect of development of blood fat reducing functional products.

This invention relates to compositions and methods relating a combination of naturally-occurring active ingredients, including active agents unrelated to statins, useful for the regulation total blood cholesterol. The inventive combination of active ingredients, including policosanol, mevinolic acid from dry yeast extract of red rice, dry extract of Lespedeza captitata, and dry grape seed extract, interrupts or inhibits the metabolic pathway leading to biosynthesis of cholesterol and cholesterol ester at multiple points and may also reduce high triglyceride levels. The present invention may be used to achieve normal blood serum LDL cholesterol concentrations and establish a healthy balance between LDL and HDL, all while significantly reducing the risk of statin-related side effects.

Provided are a compound of Formula (I) as an FTO inhibitor with improved and selective FTO inhibition, a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.

The invention discloses application of lactobacillus rhamnosus cytoplasmic membrane vesicles in preparation of a medicine for treating non-alcoholic fatty liver, and relates to the technical field of microorganisms. The medicine is used for reducing the content of cholesterol, triglyceride, glutamic oxalacetic transaminase, high-density lipoprotein cholesterol and malondialdehyde in serum; the content of cholesterol and / or triglyceride in the liver tissue is reduced; at least one of reducing liver inflammatory response and / or reducing lipid deposition caused by a high fat diet; the non-alcoholic fatty liver disease is caused by high fat diet. The lactobacillus rhamnosus cytoplasmic membrane vesicles provided by the invention can effectively relieve metabolism and liver inflammation of organisms and delay the progress of fatty liver diseases caused by high fat diet.

The invention discloses a biomarker for liver cancer diagnosis and a prognosis method thereof, and relates to the field of medical biological detection, and the biomarker for liver cancer diagnosis comprises a TATA binding protein related factor 3 and a sterol regulatory element binding protein 2; the expression levels of the TATA binding protein related factor 3 and the sterol regulatory element binding protein 2 are subjected to immunohistochemical detection, and when the immunohistochemical score of the TATA binding protein related factor 3 is greater than or equal to 2 +, the TATA binding protein related factor 3 is highly expressed; when the immunohistochemical score of the sterol regulatory element binding protein 2 is greater than or equal to 2 +, the sterol regulatory element binding protein 2 is highly expressed; according to the biomarker for liver cancer diagnosis and the prognosis method of the biomarker, liver cancer patients with poor prognosis can be accurately screened out by detecting the expression level and serum cholesterol concentration of the TATA binding protein related factor 3 and the sterol regulating element binding protein 2, a basis is provided for personalized treatment, and the diagnosis accuracy is remarkably improved.

The invention particularly relates to an enzyme immobilized hollow multi-shell structure bionic artificial cell for accurately detecting cholesterol, which is characterized in that the artificial cell comprises a metal oxide / carbonate hollow multi-shell structure, an enzyme and an artificial cell membrane, the artificial cell membrane is uniformly distributed on the surface of the hollow multi-shell structure, and the enzyme is uniformly loaded in an internal cavity. The simple and safe preparation method of the artificial cell membrane can avoid toxicity and mechanical damage in a traditional coating method, and the layer-by-layer nested hollow multi-shell structure realizes structural simulation of cells and endows the cells with selective permeability and long-term stability of enzyme. The artificial cell has efficient mass transfer performance, accurate and rapid detection of cholesterol in a solution and serum is realized through enzymatic cascade catalytic reaction, the detection range is 50-300 [mu] M, and the lowest detection limit is as low as 4.9 [mu] M. The method can be applied to serum cholesterol detection, cholesterol detection is achieved through an artificial intelligence method based on an image recognition model, and the method is expected to be used for convenient detection of cholesterol.